ClinicalTrials.gg
Not yet recruitingNCT07264010Updated Dec 4, 2025

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

A Phase 2/3 interventional study of Sorafenib (SORA) and Venetoclax (VEN) in Acute Myeloid Leukaemia (AML) and Measurable Residual Disease (MRD), sponsored by Nanfang Hospital, Southern Medical University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Nanfang Hospital, Southern Medical University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies testing sorafenib in Leukemia, Myeloid, Acute — 2 open to participants now, 6 under way, 1 of them phase 3. Sorafenib · Leukemia, Myeloid, Acute.

Planned enrollment
8th of 27
87 · median 48
Started
2025
the only one that year
Phase 2/3
2 of 27
1 open now
Registered
27th of 27
by date
Lead sponsor
3 of 27
Nanfang Hospital, Southern Medical University

Among the 27 studies testing sorafenib in Leukemia, Myeloid, Acute, this one is the 8th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 27th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

2 of the 27 studies testing sorafenib in Leukemia, Myeloid, Acute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sorafenib

Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sorafenib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

03

Conditions studied

  • Acute Myeloid Leukaemia (AML)
  • Measurable Residual Disease (MRD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary signing of form;
  • Liver and kidney function: Blood ≤ 35 μ mol/L, /ALT \< 2 times the , blood creatinine ≤ 150 μ mol/L;
  • Normal heart function (EF ≥ 50%, I/II);
  • Physical condition score 0-2 ( score);
  • Non pregnant and lactating women. For all women of childbearing age, a pregnancy test must be conducted to determine hCG levels in order to exclude pregnancy status;
  • For all men of childbearing age, measures must be taken during sorafenib treatment until 3 months after discontinuation.

Exclusion criteria

Exclusion Criteria:

  • Acute promyelocytic leukemia;
  • Hematological non-remisssion or recurrence;
  • Uncontrolled infection or grade 3-4 (GVHD);
  • Allergies or to any of the drugs involved in the protocol;
  • Severe organ dysfunction such as heart, liver, kidneys, lungs, etc.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    SORA+VEN

    sorafenib combined with venetoclax

    Drug: Sorafenib (SORA) · Drug: Venetoclax (VEN)

Interventions

06

What researchers measure

Primary outcomes

  1. Molecular response rate after three courses of treatment

    After three courses of treatment, MRD level decreased ≥1 log10 compared with the pre-treatment

    Time frame: 1 year

Secondary outcomes

  1. MRD negative rates after three courses of treatment

    MRD negative rates after three courses of treatment

    Time frame: 1 year

  2. Cumulative incidence of relapse (CIR)

    Will calculate time from hematological complete rate until relapse.

    Time frame: 3 year

  3. Event-free survival (EFS)

    Will calculate time from assignment until relapse or disease progression.

    Time frame: 3 year

  4. Overall survival (OS)

    Will calculate time from assignment until death from any cause.

    Time frame: 3 year

  5. Adverse events (AEs)

    Treatment-related AEs were defined as those that occurred from the first dose until 30 days after the discontinuation of treatment. The severity of AEs was graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0, except for haematoloical adverse events. Grade 4 hematological adverse events were defined as either an absolute neutrophil count less than 0.5×10⁹cells per L or a platelet count less than 20×10⁹per L.

    Time frame: 3 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 31 phase 2/3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 86. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2025
First posted
Dec 4, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2028
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07264010
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Dec 4, 2025

Study contacts

Qifa Liu
Contact
liuqifa628@163.com
+86-020-62787883
Pengcheng Shi
Contact
shpch283@163.com
+86-020-61641615

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sorafenib · Venetoclax

Start the discussion